De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Astellas Pharma Toekomstige groei

Future criteriumcontroles 3/6

Astellas Pharma zal naar verwachting groeien in winst en omzet met respectievelijk 30.8% en 1.7% per jaar. De winst per aandeel zal naar verwachting groeien met 31% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.4% zijn.

Belangrijke informatie

30.8%

Groei van de winst

31.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	13.8%
Inkomstengroei	1.7%
Toekomstig rendement op eigen vermogen	12.4%
Dekking van analisten	Good
Laatst bijgewerkt	23 Sep 2024

Recente toekomstige groei-updates

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04

Recent updates

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 24

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 03

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Aug 20

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 26

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 29

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Feb 29

Winst- en omzetgroeiprognoses

TSE:4503 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	1,938,241	210,791	302,090	382,395	15
3/31/2026	1,816,915	139,503	281,061	339,842	16
3/31/2025	1,747,254	79,183	261,893	335,034	14
6/30/2024	1,701,806	21,519	92,795	172,877	N/A
3/31/2024	1,603,672	17,045	100,981	172,475	N/A
12/31/2023	1,543,324	4,198	136,404	216,089	N/A
9/30/2023	1,523,572	38,090	151,562	236,992	N/A
6/30/2023	1,511,818	107,031	205,852	291,133	N/A
3/31/2023	1,518,619	98,714	239,438	327,767	N/A
12/31/2022	1,468,235	136,430	183,399	260,759	N/A
9/30/2022	1,406,682	148,911	214,107	257,916	N/A
6/30/2022	1,351,811	118,211	215,849	266,193	N/A
3/31/2022	1,296,163	124,086	205,277	257,444	N/A
12/31/2021	1,300,914	120,167	236,959	290,559	N/A
9/30/2021	1,285,714	119,360	248,993	331,268	N/A
6/30/2021	1,268,702	100,863	261,235	325,326	N/A
3/31/2021	1,249,528	120,589	229,402	306,843	N/A
12/31/2020	1,253,215	138,307	196,679	276,851	N/A
9/30/2020	1,265,853	139,722	146,751	235,299	N/A
6/30/2020	1,273,678	187,306	135,534	236,186	N/A
3/31/2020	1,300,843	195,411	144,110	221,998	N/A
12/31/2019	1,289,855	220,751	151,021	225,239	N/A
9/30/2019	1,309,722	246,925	182,693	248,203	N/A
6/30/2019	1,311,397	226,224	176,251	228,863	N/A
3/31/2019	1,306,348	222,265	206,502	258,630	N/A
12/31/2018	1,305,901	213,600	254,876	300,955	N/A
9/30/2018	1,307,658	186,429	265,976	309,442	N/A
6/30/2018	1,306,830	176,770	246,040	290,301	N/A
3/31/2018	1,300,316	164,679	N/A	312,614	N/A
12/31/2017	1,305,521	182,515	N/A	264,549	N/A
9/30/2017	1,299,746	185,754	N/A	260,795	N/A
6/30/2017	1,296,484	194,556	N/A	276,954	N/A
3/31/2017	1,311,665	218,701	N/A	235,612	N/A
12/31/2016	1,312,627	207,940	N/A	325,459	N/A
9/30/2016	1,336,878	205,818	N/A	308,800	N/A
6/30/2016	1,366,799	215,678	N/A	302,245	N/A
3/31/2016	1,372,706	193,687	N/A	313,737	N/A
12/31/2015	1,360,153	185,659	N/A	207,806	N/A
9/30/2015	1,340,307	168,805	N/A	182,815	N/A
6/30/2015	1,295,761	144,617	N/A	156,675	N/A
3/31/2015	1,247,259	135,856	N/A	187,686	N/A
12/31/2014	1,205,276	124,154	N/A	N/A	N/A
9/30/2014	1,177,660	112,663	N/A	224,809	N/A
6/30/2014	1,159,218	104,614	N/A	N/A	N/A
3/31/2014	1,139,909	90,874	N/A	214,257	N/A
12/31/2013	1,137,824	79,679	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 4503 ( 30.8% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van 4503 ( 30.8% per jaar) zal naar verwachting sneller groeien dan de JP markt ( 8.7% per jaar).

Hoge groeiwinsten: De winst van 4503 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 4503 ( 1.7% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 4503 ( 1.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 4503 zal naar verwachting over 3 jaar laag zijn ( 12.4 %).

Astellas Pharma Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 21%

Consensus EPS estimates fall by 15%

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 11%

Recent updates

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Upcoming dividend of JP¥37.00 per share

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 21%

Consensus EPS estimates fall by 15%

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Consensus EPS estimates fall by 16%

Final dividend of JP¥37.00 announced

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Astellas Pharma (TSE:4503) A Risky Investment?

Consensus EPS estimates fall by 11%

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Consensus EPS estimates fall by 16%

Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Consensus EPS estimates fall by 14%

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Upcoming dividend of JP¥35.00 per share

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Consensus EPS estimates fall by 11%

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

New minor risk - Profit margin trend

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Upcoming dividend of JP¥35.00 per share at 3.3% yield

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer

Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY

European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence